ArticleTranslational cancer research2025
CXCR3 enhanced murine chimeric antigen receptor T cells in the treatment of solid tumors.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy.Cancer research · 2026Review
- CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- CAR-T cell signaling dynamics, rational design principles and artificial intelligence for next-generation chimeric antigen receptors.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chimeric antigen receptor T cell (CAR-T) therapy has achieved remarkable success in the treatment of hematologic malignancies, but its efficacy against solid tumors remains limited. This limitation primarily arises from the physical and molecular barriers that restrict CAR-T infiltration. The CXCL10-CXCR3 axis plays a critical role in mediating immune cell migration. Notably, elevated CXCR3 expression in solid tumors is correlated with improved immune infiltration and patient survival. Furthermore, the downregulation of CXCR3 in CD8 Methods: We constructed murine CAR-Ts (mCAR-Ts) targeting EGFRvIII (a tumor-specific antigen) and overexpressing CXCR3, which we named EGFRvIII·mCAR-T-CXCR3 cells. These cells were functionally characterized by Results: The EGFRvIII·mCAR-T-CXCR3 cells showed enhanced cytotoxic activity and CXCL10-directed migration Conclusions: CXCR3 overexpression potentiates the anti-tumor capacity of CAR-Ts in solid tumors by enhancing tumor infiltration. This strategy provides a promising approach for overcoming the current limitations of CAR-T therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.